Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
Meta-analysis of 26 studies (27,933 MZ/SZ alpha-1 antitrypsin heterozygotes vs 547,961 controls): heterozygotes had higher odds of fibrosis (OR 2.14), cirrhosis (OR 2.24) and liver transplantation (OR 2.28), with modestly raised liver enzymes but similar steatosis.
Meta-analysisn = 575,894
Syanda et al. Meta-Analysis: Redefining Liver Disease Risk in Heterozygous Alpha-1 Antitrypsin DeficiencyMeta-analysis of 25 samples (8 individual-participant data, 17 published; 488,765 participants): purpose in life was associated with lower mortality (HR 0.76), attenuated but persisting after adjustment for behavioural and clinical factors (HR 0.85) or depression (HR 0.91).
Meta-analysisn = 488,765
Sutin et al. Purpose in life and mortality: A meta-analysis of the published literature and individual-participant data of 488,765 participants followed for up to 32 yearsMultiancestry GWAS meta-analysis of stool frequency in 268,606 individuals found 21 loci (10 novel) and genetic links to IBS; fine-mapping implicated vitamin B1 metabolism, and in 98,449 UK Biobank participants thiamine intake was associated with stool frequency.
Meta-analysisn = 268,606
Díaz-Muñoz et al. Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motilityNetwork meta-analysis of 262 trials (99 791 adults with overweight or obesity, 19 drugs): versus lifestyle alone, tirzepatide (-14.9%) and CagriSema (-14.8%) gave most 1-year weight loss; larger benefits came with more harms and discontinuation. Few cut cardiovascular events.
Meta-analysisn = 99,791
Nong et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysisMeta-analysis of 95 observational studies (63,988 hospital healthcare workers and first responders): pooled latent TB positivity was 22% by IGRA vs 38% by TST; TST, unlike IGRA, positivity was associated with higher BCG vaccination rates.
Meta-analysisn = 63,988
Alahmari et al. Interferon-gamma release assays versus tuberculin skin test for latent tuberculosis infection positivity among healthcare workers and first responders: a systematic review and meta-analysisSystematic review of 190 studies (127 meta-analysed, 43,006 athletes): pooled prevalence of eating disorders or disordered eating in athletes was 20.0%, with no significant difference by training level or screening method; estimates varied by instrument (11.9% to 28.3%).
Meta-analysisn = 43,006
Nasser et al. Prevalence of eating disorders and disordered eating in athletes: a systematic review and meta-analysisSystematic review of 33 studies (27 meta-analysed; 31,834 children): anxiety (OR 2.67) and depression (OR 1.93) were associated with oral health problems, notably bruxism and temporomandibular disorders in subgroups, with high heterogeneity.
Meta-analysisn = 31,834
Wang et al. Anxiety and depression associated oral health problems in pediatric populations: A systematic review and meta-analysisNetwork meta-analysis of 98 RCTs (28,920 people with chronic non-cancer pain): melatonin improved sleep quality vs placebo (SMD -0.60; moderate certainty) without raised adverse events; ten other agents helped sleep but with low-certainty evidence and more adverse events.
Meta-analysisn = 28,920
Chang et al. Comparative effectiveness and safety of pharmacological interventions for sleep outcomes in chronic non-cancer pain: a systematic review and network meta-analysisMeta-analysis of 126 double-blind RCTs of acute migraine treatments (24,614 placebo-treated participants): pooled 2-hour pain freedom with placebo was 11% (PI 4%-27%), higher with intranasal or subcutaneous than oral placebo, and rose significantly over time.
Meta-analysisn = 24,614
Makita et al. Magnitude and Determinants of Placebo Response in Acute Migraine Trials: A Systematic Review and Meta-AnalysisMeta-analysis of 58 phase 3 RCTs (22 590 patients): treatment-related peripheral edema affected 2.80% on immune checkpoint inhibitor monotherapy, 4.96% with chemotherapy and 8.73% with targeted therapy; monotherapy vs chemotherapy OR 0.45 (95% CI 0.27–0.73).
Meta-analysisn = 22,590
Markus et al. Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis